- Home
- General Medicine
- BASIS Study Clinical Trial Highlights Marstacimab Efficacy and Safety
6mo3 min read
Medical Article
Introduction Hemophilia A (HemA) and Hemophilia B (HemB) are X-linked bleeding disorders characterized by deficiencies in coagulation factors VIII (FVIII) and IX (FIX), respectively (1). Severe hemophilia (FVIII or FIX <0.01 IU/mL or <1% of normal) leads to frequent spontaneous or trauma-related bleeds, mainly in joints, muscles, and soft tissues (

BASIS Study Clinical Trial Highlights Marstacimab Efficacy and Safety
26 Reached
Similar Content

Woman presented with Fever of Unknown Origin
7733 Reached93 Comments19 Likes

How Physicians Should Manage Stress?
35339 Reached151 Comments202 Likes

Switching from Premixed Insulin to Basal Insulin with OADs
1083 Reached2 Comments6 Likes

Male with Jaw Pain and Abdominal Bloating
790 Reached24 Comments26 Likes

Case of Adolescent with Severe Macrocytic Anaemia
52939 Reached501 Comments51 Likes
